You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Caspofungin acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for caspofungin acetate and what is the scope of patent protection?

Caspofungin acetate is the generic ingredient in two branded drugs marketed by Merck, Areva Pharms, Cipla, Fresenius Kabi Usa, Gland, Hengrui Pharma, Norvium Bioscience, and Xellia Pharms Aps, and is included in eight NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Caspofungin acetate has fourteen patent family members in fourteen countries.

There are six drug master file entries for caspofungin acetate. Eight suppliers are listed for this compound.

Drug Prices for caspofungin acetate

See drug prices for caspofungin acetate

Recent Clinical Trials for caspofungin acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 4
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
Children's Oncology GroupPhase 3

See all caspofungin acetate clinical trials

Pharmacology for caspofungin acetate
Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CANCIDAS for Injection caspofungin acetate 50 mg/vial and 70 mg/vial 021227 1 2009-06-26

US Patents and Regulatory Information for caspofungin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gland CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 207092-002 Sep 29, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gland CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 207092-001 Sep 29, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cipla CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 209489-002 Jul 12, 2018 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 206110-002 Dec 30, 2016 AP RX No No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Areva Pharms CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 211263-001 Oct 1, 2021 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for caspofungin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for caspofungin acetate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0620232 C300076 Netherlands ⤷  Sign Up PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232 44/2001 Austria ⤷  Sign Up PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232 SPC/GB02/002 United Kingdom ⤷  Sign Up A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232 2001/029 Ireland ⤷  Sign Up PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232 01C0054 France ⤷  Sign Up PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.